blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3013425

EP3013425 - LEUKOTOXIN FOR USE IN THE TREATMENT OF OCULAR DISEASE [Right-click to bookmark this link]
Former [2016/18]TREATMENT AND DIAGNOSIS OF OCULAR DISEASE
[2020/12]
StatusNo opposition filed within time limit
Status updated on  16.07.2021
Database last updated on 13.11.2024
FormerThe patent has been granted
Status updated on  07.08.2020
FormerGrant of patent is intended
Status updated on  21.04.2020
FormerExamination is in progress
Status updated on  18.05.2018
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024  [2024/41]
Applicant(s)For all designated states
Rutgers, the State University of New Jersey
Old Queen's
Somerset Street
New Brunswick, NJ 08909 / US
For all designated states
Actinobac Biomed, Inc.
15 Pelham Road
Kendall Park, NJ 08824 / US
[2016/18]
Inventor(s)01 / KACHLANY, Scott
546 Country Club Road
Bridgewater, NJ 08807 / US
02 / BELINKA, Benjamin
15 Pelham Road
Kendall Park, NJ 08824 / US
 [2016/18]
Representative(s)Zacco GmbH
Bayerstrasse 83
80335 München / DE
[2016/18]
Application number, filing date14817083.027.06.2014
[2016/18]
WO2014US44567
Priority number, dateUS201361840045P27.06.2013         Original published format: US 201361840045 P
[2016/18]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014210454
Date:31.12.2014
Language:EN
[2014/53]
Type: A1 Application with search report 
No.:EP3013425
Date:04.05.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 31.12.2014 takes the place of the publication of the European patent application.
[2016/18]
Type: B1 Patent specification 
No.:EP3013425
Date:09.09.2020
Language:EN
[2020/37]
Search report(s)International search report - published on:US31.12.2014
(Supplementary) European search report - dispatched on:EP06.12.2016
ClassificationIPC:A61P37/06, A61P29/00, A61P37/00, A61K38/16, A61K9/00
[2017/01]
CPC:
A61K38/164 (EP,US); A61K9/0048 (EP,US); A61K9/0051 (EP,US);
A61P27/02 (EP); A61P29/00 (EP); A61P37/00 (EP);
A61P37/06 (EP) (-)
Former IPC [2016/18]A61P37/06, A61P29/00, A61P37/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/18]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:LEUKOTOXIN ZUR BEHANDLUNG VON AUGENERKRANKUNGEN[2020/12]
English:LEUKOTOXIN FOR USE IN THE TREATMENT OF OCULAR DISEASE[2020/12]
French:LEUKOTOXIN POUR LE TRAITEMENT D'UNE MALADIE OCULAIRE[2020/12]
Former [2016/18]BEHANDLUNG UND DIAGNOSE VON AUGENERKRANKUNGEN
Former [2016/18]TREATMENT AND DIAGNOSIS OF OCULAR DISEASE
Former [2016/18]TRAITEMENT ET DIAGNOSTIC D'UNE MALADIE OCULAIRE
Entry into regional phase27.01.2016National basic fee paid 
27.01.2016Search fee paid 
27.01.2016Designation fee(s) paid 
27.01.2016Examination fee paid 
Examination procedure27.01.2016Examination requested  [2016/18]
30.06.2017Amendment by applicant (claims and/or description)
22.05.2018Despatch of a communication from the examining division (Time limit: M06)
10.10.2018Reply to a communication from the examining division
29.01.2019Despatch of a communication from the examining division (Time limit: M04)
24.05.2019Reply to a communication from the examining division
07.10.2019Despatch of a communication from the examining division (Time limit: M04)
31.10.2019Reply to a communication from the examining division
22.04.2020Communication of intention to grant the patent
27.07.2020Fee for grant paid
27.07.2020Fee for publishing/printing paid
27.07.2020Receipt of the translation of the claim(s)
Opposition(s)10.06.2021No opposition filed within time limit [2021/33]
Fees paidRenewal fee
27.06.2016Renewal fee patent year 03
27.06.2017Renewal fee patent year 04
27.06.2018Renewal fee patent year 05
27.06.2019Renewal fee patent year 06
29.06.2020Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.06.2014
AL09.09.2020
AT09.09.2020
CY09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
MK09.09.2020
MT09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
[2024/41]
Former [2024/22]HU27.06.2014
AL09.09.2020
AT09.09.2020
CY09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
MK09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2023/30]HU27.06.2014
AL09.09.2020
AT09.09.2020
CY09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2023/29]HU27.06.2014
AL09.09.2020
AT09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2022/08]AL09.09.2020
AT09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/48]AL09.09.2020
AT09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
IT09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/37]AL09.09.2020
AT09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/36]AL09.09.2020
AT09.09.2020
CZ09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/28]AL09.09.2020
AT09.09.2020
CZ09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/25]AL09.09.2020
AT09.09.2020
CZ09.09.2020
EE09.09.2020
ES09.09.2020
FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/23]AT09.09.2020
CZ09.09.2020
EE09.09.2020
FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
PT11.01.2021
Former [2021/22]CZ09.09.2020
EE09.09.2020
FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
PT11.01.2021
Former [2021/21]FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RS09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
PT11.01.2021
Former [2021/18]FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RS09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
Former [2021/10]FI09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
PL09.09.2020
RS09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
Former [2021/09]FI09.09.2020
LT09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
Former [2021/08]FI09.09.2020
LT09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
Former [2021/07]FI09.09.2020
LT09.09.2020
NO09.12.2020
Documents cited:Search[XY]EP2488198  (UNIV NEW JERSEY MED [US]) [X] 12 * paragraph [0013] - paragraph [0018] * [Y] 1-15;
 [XY]WO2012125942  (UNIV NEW JERSEY MED [US], et al) [X] 12 * paragraph [0003] * * paragraph [0013] - paragraph [0016] *[Y] 1-15
International search[Y]US2006252107  (KUBOTA RYO [US], et al);
 [X]US2012263644  (KACHLANY SCOTT C [US])
by applicantWO2007062150
 US2009075883
 WO2011047011
    - KACHLANY, S. C., J Dent Res, (20100000), vol. 89, pages 561 - 570
    - MANGAN et al., Infect Immun, (19910000), vol. 59, pages 3267 - 72
    - KACHLANY, S. C. et al., Leukemia Research, (20100000), vol. 34, pages 777 - 85
    - KACHLANY, S. C. et al., Infect Immun, (20000000), vol. 68, pages 6094 - 100
    - KACHLANY, S. C. et al., Protein Expr Purif, (20020000), vol. 25, pages 465 - 71
    - WEKSLER, B. B.E. A. SUBILEAUN. PERRIEREP. CHARNEAUK. HOLLOWAYM. LEVEQUEH. TRICOIRE-LEIGNELA. NICOTRAS. BOURDOULOUSP. TUROWSKI, "Blood-brain barrier-specific properties of a human adult brain endothelial cell line", Faseb J, (20050000), vol. 19, doi:10.1096/fj.04-3458fje, pages 1872 - 4, XP002658008

DOI:   http://dx.doi.org/10.1096/fj.04-3458fje
    - WASSMER, S. C.V. COMBESF. J. CANDALI. JUHAN-VAGUEG. E. GRAU, "Platelets potentiate brain endothelial alterations induced by Plasmodium falciparum", Infect Immun, (20060000), vol. 74, pages 645 - 53
    - DIAZ et al., Microb Pathog, (20060000), vol. 40, pages 48 - 55
 WO2006US45258
 WO2010US52453
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.